Vascular Biogenics Ltd. (NASDAQ: VBLT) Spikes 25%
Vascular Biogenics, a biotechnology company specializing in cancer treatment drugs, announced news today that they would be presenting positive data for preliminary trial results in the study for Mullerian Cancer treatment at the annual ASCO conference. Shares of VBLT soared in early trading by over 25%.
VBLT develops a drug product known as VB-111 and has shown positive data in the first phase of clinical trials. Read the official PR for further information.
About Vascular Biogenics Ltd.
Vascular Biogenics Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for cancer and immune-inflammatory diseases in Israel. Its lead product candidates include VB-111, a gene-based biologic that has completed Phase II clinical trials for the treatment of recurrent glioblastoma, an aggressive form of brain cancer; in Phase II clinical trials to treat thyroid cancer; and in Phase I/II clinical trials for the treatment of ovarian cancer. The company was formerly known as Medicard Ltd. and changed its name to Vascular Biogenics Ltd. in January 2003. Vascular Biogenics Ltd. was founded in 2000 and is headquartered in Or Yehuda, Israel. – Yahoo! Finance